Evidence map›Paper›PMID 33487592›Full record

Trial reportGut2021

Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma.

Shumei Song, Qiongrong Chen, Yuan Li, Guang Lei, Ailing Scott, Longfei Huo, Cordelia Y Li, Jeannelyn Santiano Estrella, Arlene Correa, Melissa Pool Pizzi and 14 more

Open access · greenAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gut, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting.International journal of molecular sciences · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL1.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 2 institutions in 2 countries.

Shumei SongDepartment of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA ssong@mdanderson.org jajani@mdanderson.org.ORCID 0000-0002-8128-6287
Qiongrong ChenDepartment of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-6613-535X
Yuan LiDepartment of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Guang LeiExperimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ailing ScottDepartment of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Longfei HuoDepartment of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cordelia Y LiDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jeannelyn Santiano EstrellaDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Arlene CorreaDepartment of Thoracic & Cardio Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Melissa Pool PizziDepartment of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lang MaDepartment of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jiankang JinDepartment of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Bin LiuDepartment of Epigenet & Mol Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ying WangDepartment of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lianchun XiaoDepartment of Statistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wayne L HofstetterDepartment of Thoracic & Cardio Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jeffrey H LeeGastroenterology, Hepat & Nutri, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Brian WestonGastroenterology, Hepat & Nutri, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Manoop BhutaniGastroenterology, Hepat & Nutri, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Namita ShanbhagDepartment of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Randy L JohnsonCancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Boyi GanExperimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Shaozhong WeiSurgical Oncology, Hubei Cancer Hospital, Wuhan, Hubei, China.
Jaffer A AjaniDepartment of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA ssong@mdanderson.org jajani@mdanderson.org.ORCID 0000-0001-9946-0629
The University of Texas MD Anderson Cancer Center · USHubei Cancer Hospital · CN

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
The Role of Telomere Shortening in MDS-AML Pathogenesis (resubmission)R01CA160433 · NCI · JOHNS HOPKINS UNIVERSITY · PI ARMANIOS, MARY Y · 2012 to 2016
$1.7M
Prediction of Pathologic Complete Response by Gene Expression Profiling in EsophaR01CA138671 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AJANI, JAFFER A. · 2010 to 2014
$1.5M
Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junctionR01CA172741 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AJANI, JAFFER A. · 2013 to 2017
$1.4M
Molecular Biomarkers as Classifiers to Individualize Therapy of Esophagus CancerR21CA129906 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AJANI, JAFFER A. · 2009 to 2010
$367k
Molecular Markers of Response to Chemoradiation in Localized Esophageal CancerR21CA127672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AJANI, JAFFER A. · 2008 to 2009
$312k
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA138671NCI NIH HHS R01 CA160433NCI NIH HHS R01 CA172741NCI NIH HHS R21 CA127672NCI NIH HHS R21 CA129906
6 · The paper itself

Abstract

objectiveGastro-oesophageal cancers (GEC) are resistant to therapy and lead to poor prognosis. The cancer stem cells (CSCs) and antiapoptotic pathways often confer therapy resistance. We sought to elucidate the antitumour action of a BCL-2 inhibitor, AT101 in GEC in vitro, in vivo and in a clinical trial.

methodsExtensive preclinical studies in vitro and in vivo were carried out to establish the mechanism action of AT101 on targeting CSCs and antiapoptotic proteins. A pilot clinical trial in patients with GEC was completed with AT-101 added to standard chemoradiation.

resultsOverexpression of BCL-2 and MCL-1 was noted in gastric cancer tissues (GC). AT-101 induced apoptosis, reduced proliferation and tumour sphere formation in MCL-1/BCL-2 high GC cells. Interestingly, AT101 dramatically downregulated genes (

conclusionsOur preclinical and clinical data suggest that AT-101 overcomes resistance by targeting CSCs pathways suggesting a novel mechanism of action of AT101 in patients with GEC.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicApoptosisCell Line, TumorDisease Models, AnimalDocetaxelEsophageal NeoplasmsFemaleGossypolHumansMaleMiceMiddle AgedNeoplastic Stem CellsPilot ProjectsProto-Oncogene Proteins c-bcl-2Antineoplastic Agents, PhytogenicDocetaxelGossypolgossypol acetic acidProto-Oncogene Proteins c-bcl-2gastrointestinal cancergene expressionmolecular oncologyoesophageal cancer

Identifiers

PMID33487592
PMCPMC9720890
OpenAlexW3125501170

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.